Remedent, Inc. (REMI)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Remedent, Inc. (REMI) trades at $0.00. Remedent, Inc. specializes in researching, developing, manufacturing, and distributing oral care and cosmetic dentistry products. Market cap: $13,997, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for REMI: REMI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates REMI against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
REMI: 1/1 perspectives are bearish.
How is this calculated? →Remedent, Inc. (REMI) Healthcare & Pipeline Overview
Remedent, Inc. provides oral care and cosmetic dentistry products, including veneers and teeth whitening solutions, catering to dental professionals in approximately 30 countries. With a focus on innovation and distribution through both internal sales and third-party channels, Remedent operates in a competitive market with a negative profit margin.
What Is the Investment Thesis for REMI?
Remedent, Inc. operates in the niche market of cosmetic dentistry with products like River8 and GlamSmile veneers. The company's gross margin of 61.2% indicates potential profitability if operational efficiencies are improved. However, the negative P/E ratio of -0.05 and a market cap of 14K suggest financial instability. Growth catalysts include expanding its distribution network and increasing adoption of its SmileMe Mirror and SmileSketch technologies. The company's success hinges on effectively marketing its products and managing its operational costs to achieve profitability. Investors should closely monitor the company's ability to improve its financial performance and capitalize on growth opportunities in the cosmetic dentistry market. The company's small size and OTC listing add additional risk factors.
Based on FMP financials and quantitative analysis
REMI Key Highlights
- Gross margin of 61.2% indicates potential for profitability if operational efficiencies improve.
- Negative P/E ratio of -0.05 reflects current losses and potential valuation challenges.
- Market capitalization of 14K signifies a small company with limited financial resources.
- Profit margin of -27.8% highlights the company's struggle to achieve profitability.
- Beta of -0.48 suggests the stock is less volatile than the market, but also less responsive to market upswings.
Who Are REMI's Competitors?
REMI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| NYXH Nyxoah S.A. | $1.75 | +1.74% | $69.31M | 69 |
| KMTS Kestra Medical Technologies, Ltd. | $27.70 | +2.67% | $1.62B | 67 |
| ZTEK Zentek Ltd. | $0.46 | +2.88% | $49.90M | 63 |
| OMIC Singular Genomics Systems, Inc. | $20.01 | +0.00% | $50.77M | 61 |
| BLMHF Bloom Health Partners Inc. | $0.11 | +0.00% | $5.22M | 51 |
| FSPKF Fisher & Paykel Healthcare Corporation Limited | $22.52 | +0.00% | $13.23B | 51 |
| CZMWY Carl Zeiss Meditec AG | $32.76 | +3.56% | $2.87B | 51 |
| STAA STAAR Surgical Company | $27.45 | -1.21% | $1.37B | 51 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are REMI's Key Strengths?
- Specialized product portfolio in cosmetic dentistry.
- Established distribution network in multiple countries.
- Proprietary veneer designs and integrated marketing solutions.
- High gross margin (61.2%) indicates pricing power.
What Are REMI's Weaknesses?
- Negative profit margin (-27.8%) indicates financial instability.
- Small market capitalization ($0.00B) limits access to capital.
- Limited number of employees (3) suggests operational constraints.
- OTC listing indicates higher risk and lower liquidity.
What Could Drive REMI Stock Higher?
- Potential partnerships with dental clinics to expand distribution (timeline: ongoing).
- Launch of new teeth whitening products for at-home use (timeline: 1-2 years).
- Increased adoption of SmileMe Mirror and SmileSketch technologies by dental professionals.
- Expansion into emerging markets with growing demand for cosmetic dentistry.
- Development of new and innovative veneer products (timeline: 3-5 years).
What Are the Key Risks for REMI?
- Financial-distress signal — its Altman Z-Score of -5.70 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-11.3%) — the business is not currently generating profit on shareholder capital.
- Intense competition from larger dental product manufacturers.
- Regulatory changes in the dental industry.
- Economic downturns affecting consumer spending on cosmetic procedures.
- Product liability claims related to dental implants or veneers.
- Financial instability due to negative profit margin.
What Are the Growth Opportunities for REMI?
- Expansion into emerging markets represents a significant growth opportunity for Remedent. The increasing disposable incomes and growing awareness of cosmetic dentistry in countries like India and Brazil could drive demand for Remedent's products. Establishing partnerships with local distributors and tailoring products to meet the specific needs of these markets could facilitate market entry. While specific market size data is unavailable, the overall dental market in emerging economies is projected to grow substantially over the next five years, providing a favorable backdrop for Remedent's expansion efforts. Timeline: 2-3 years.
- Increased adoption of digital dentistry solutions, such as the SmileMe Mirror and SmileSketch, presents another growth avenue. These technologies enhance the patient consultation process and improve treatment planning, which can lead to increased sales of Remedent's core products. By offering comprehensive digital solutions, Remedent can differentiate itself from competitors and attract dental professionals seeking to modernize their practices. The market for digital dentistry is expected to grow at a CAGR of 10-15% over the next five years, driven by advancements in imaging technology and software. Timeline: Ongoing.
- Development of new and innovative veneer products could drive revenue growth. Investing in research and development to create veneers with improved aesthetics, durability, and ease of application can attract new customers and retain existing ones. Collaborating with dental professionals to gather feedback and incorporate their insights into product development can ensure that new products meet the evolving needs of the market. The market for dental veneers is estimated at $2.5 billion globally and is expected to grow at a steady pace of 5-7% annually. Timeline: 3-5 years.
- Strategic partnerships with dental clinics and group practices can expand Remedent's distribution network and increase product visibility. By offering exclusive deals and marketing support to partner clinics, Remedent can secure a consistent stream of sales and build brand loyalty. These partnerships can also provide valuable opportunities for product demonstrations and training sessions, which can further drive adoption. The trend towards consolidation in the dental industry, with the emergence of large group practices, makes this strategy particularly relevant. Timeline: Ongoing.
- Expansion of the company's teeth whitening product line to include at-home solutions could tap into the growing consumer market for over-the-counter dental products. Developing safe and effective whitening kits that can be used at home can generate additional revenue streams and increase brand awareness. Marketing these products through online channels and retail partnerships can reach a wider audience. The global teeth whitening market is estimated at $7 billion and is expected to grow at a CAGR of 4-6% over the next five years. Timeline: 1-2 years.
What Opportunities Does REMI Have?
- Expansion into emerging markets with growing demand for cosmetic dentistry.
- Increased adoption of digital dentistry solutions.
- Development of new and innovative veneer products.
- Strategic partnerships with dental clinics and group practices.
What Threats Does REMI Face?
- Intense competition from larger dental product manufacturers.
- Regulatory changes in the dental industry.
- Economic downturns affecting consumer spending on cosmetic procedures.
- Product liability claims related to dental implants or veneers.
What Are REMI's Competitive Advantages?
- Proprietary veneer designs (River8, GlamSmile).
- Integrated marketing solutions for dental practices (SmileMe Mirror, SmileSketch).
- Established distribution network in approximately 30 countries.
- Specialized knowledge in cosmetic dentistry products.
What Does REMI Do?
Founded in 1986 and headquartered in Ghent, Belgium, Remedent, Inc. operates within the healthcare sector, specifically focusing on the medical instruments and supplies industry. The company researches, designs, develops, manufactures, and distributes oral care and cosmetic dentistry products. Its core offerings include professional veneers and teeth whitening products, catering to both professional and over-the-counter markets. A key product is River8, a prefab veneer designed for dentists to easily find the right fit for patients requiring minor reshaping. GlamSmile veneers, ultra-thin claddings attached to the front of teeth, are another significant offering. Remedent also provides integrated marketing solutions for dental practices, such as the SmileMe Mirror, which facilitates smile consultations in approximately 10 minutes. SmileSketch, a simulation software, allows dentists to create visual sketches of potential cosmetic outcomes for patients. The company further offers various Treatment Pages to educate patients on the benefits of specific treatments, along with the Condor intra-oral 3D scanner. Remedent extends its product line to include dental implant solutions and related treatment concepts. Remedent distributes its products to dental professionals in approximately 30 countries across Asia, Europe, the Middle East, Canada, and the United States. The company utilizes both an internal sales force and third-party distributors to reach its customer base. Despite its global presence, Remedent faces challenges reflected in its negative profit margin of -27.8%.
What Products and Services Does REMI Offer?
- Researches and designs oral care products.
- Develops cosmetic dentistry solutions.
- Manufactures veneers for dental professionals.
- Distributes teeth whitening products.
- Offers dental implant solutions.
- Provides intra-oral 3D scanners (Condor).
- Creates smile simulation software (SmileSketch).
- Markets integrated consultation systems (SmileMe Mirror).
How Does REMI Make Money?
- Sells veneers (River8, GlamSmile) to dental professionals.
- Provides teeth whitening products for professional and over-the-counter use.
- Offers dental implant solutions.
- Generates revenue through direct sales and third-party distributors.
What Industry Does REMI Operate In?
Remedent, Inc. operates within the global cosmetic dentistry market, which is characterized by increasing demand for aesthetic dental procedures. The market includes veneers, teeth whitening, and dental implants. Competition includes companies like CYPS, DGEN, EMGE, NMRD, and NMXS, which offer similar products and services. The industry is driven by technological advancements in dental materials and procedures, as well as a growing emphasis on oral hygiene and aesthetics. Remedent's success depends on its ability to innovate, differentiate its products, and effectively market them to dental professionals.
Who Are REMI's Key Customers?
- Dental professionals (dentists, orthodontists).
- Dental clinics and group practices.
- Patients seeking cosmetic dentistry solutions.
- Third-party distributors of dental products.
ROE -11%Key Financial Metrics
Return on equity for Remedent, Inc. stands at -11.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -5.0%, showing how much profit it generates from its asset base. A current ratio of 0.33 means current liabilities exceed short-term assets, a liquidity point worth watching.
Remedent, Inc. (REMI) Valuation Context
Valued at 14K, REMI is classified as a micro-cap stock.
Company Profile
Remedent, Inc. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Gent, BE. The company is led by CEO Guy De Vreese. REMI has traded publicly since 2006.
F-Score 4/9Financial Health
Remedent, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -5.70 places it in the distress zone, a signal of elevated financial risk.
Net sellingInsider Activity
The most recent 12 insider filings for Remedent, Inc. break down as 10 sales and 2 purchases. On net that is roughly 3.5M shares disposed (about $177K), a signal worth weighing alongside the fundamentals.
REMI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Recent insider buying indicates confidence in Remedent's growth potential, suggesting a positive outlook from those closest to the company.
- Community sentiment has shifted positively with increased discussions around Remedent's innovative dental products, reflecting growing interest.
- Analysts note that Remedent's unique market position in dental aesthetics could attract new partnerships, enhancing revenue streams.
- Recent product launches have generated buzz, positioning the company favorably within the dental industry and attracting attention from potential investors.
Bear Case
- Concerns about overall market conditions may dampen investor enthusiasm for smaller companies like Remedent, impacting sentiment negatively.
- Social media discussions reveal skepticism about the scalability of Remedent's business model, with some questioning its long-term viability.
- Recent competition in the dental aesthetics space has intensified, potentially threatening Remedent's market share and profitability.
- Insider selling in the last month raises red flags, leading to speculation about potential challenges the company may face ahead.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
REMI Latest News
No recent news available for REMI.
REMI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for REMI.
Price Targets
Wall Street price target analysis for REMI.
REMI MoonshotScore
What does this score mean?
The MoonshotScore rates REMI's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Guy De Vreese
Managing Director
Guy De Vreese serves as the Managing Director of Remedent, Inc. His responsibilities include overseeing the company's operations, strategic direction, and overall performance. Information regarding his prior experience and educational background is not available. As the head of a small team of 3 employees, his leadership is critical to the company's success.
Track Record: Due to limited information available, it is difficult to assess Guy De Vreese's specific achievements and strategic decisions at Remedent. The company's current financial performance, including a negative profit margin and small market capitalization, suggests ongoing challenges. His ability to navigate these challenges and drive the company towards profitability will be crucial.
REMI OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Remedent, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosures and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the potential for fraud, lack of transparency, and limited liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in REMI.
- Low liquidity can make it difficult to buy or sell shares.
- Potential for price manipulation due to low trading volume.
- Lack of regulatory oversight increases the risk of fraud.
- Small market capitalization and financial instability.
- Verify the company's financial statements and disclosures.
- Research the background and experience of the management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Understand the risks associated with investing in OTC stocks.
- Monitor trading volume and price fluctuations.
- Consult with a financial advisor.
- Company has been in business since 1986.
- Products are sold in approximately 30 countries.
- Company has a gross margin of 61.2%.
- Company has a website and actively markets its products.
- Company has patents or trademarks on its products.
Remedent, Inc. Healthcare Stock: Key Questions Answered
What does Remedent, Inc. do?
Remedent, Inc. researches, develops, manufactures, and distributes oral care and cosmetic dentistry products. Its primary offerings include professional veneers, such as River8 and GlamSmile, and teeth whitening products for both professional and over-the-counter use. The company also provides digital dentistry solutions like SmileMe Mirror and SmileSketch, along with dental implant solutions. Remedent sells its products to dental professionals in approximately 30 countries through its internal sales force and third-party distributors, focusing on enhancing dental aesthetics and patient consultation processes.
What do analysts say about REMI stock?
As of 2026-03-17, formal analyst ratings for Remedent, Inc. (REMI) are unavailable, likely due to its OTC listing and small market capitalization. Key valuation metrics, such as the negative P/E ratio of -0.05, reflect the company's current losses. Investors should focus on the company's ability to improve its financial performance, capitalize on growth opportunities in the cosmetic dentistry market, and manage risks associated with its OTC listing. Independent due diligence is crucial for assessing REMI's potential.
What are the main risks for REMI?
Remedent, Inc. faces several risks, including intense competition from larger dental product manufacturers, potential regulatory changes in the dental industry, and economic downturns affecting consumer spending on cosmetic procedures. Product liability claims related to dental implants or veneers also pose a risk. Additionally, the company's financial instability, as indicated by its negative profit margin and OTC listing, presents significant challenges. Investors should carefully consider these risks before investing in REMI.
What are the key factors to evaluate for REMI?
Evaluate REMI on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does REMI data refresh on this page?
REMI prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven REMI's recent stock price performance?
Remedent, Inc. (REMI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized product portfolio in cosmetic dentistry. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider REMI overvalued or undervalued right now?
Valuing Remedent, Inc. (REMI) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying REMI?
Before investing in Remedent, Inc. (REMI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on the company's financials and operations.
- OTC listing indicates higher risk and lower liquidity.
- AI analysis pending for REMI.